<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547465</url>
  </required_header>
  <id_info>
    <org_study_id>230/HĐĐĐ-ĐHYD</org_study_id>
    <nct_id>NCT04547465</nct_id>
  </id_info>
  <brief_title>2D Speckle-tracking Echocardiography in Chemotherapy-induced Cardiomyopathy With Cardiovascular Risk Factors</brief_title>
  <official_title>The Role of 2D Speckle-tracking Echocardiography in Diagnosis Chemotherapy-induced Cardiomyopathy in Breast Cancer Patients With High Cardiovascular Risk Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gia Dinh People Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gia Dinh People Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study is to evaluate the role of 2D speckle-tracking echocardiography in&#xD;
      diagnosis chemotherapy related left ventricular dysfunction in breast cancer patients with&#xD;
      cardiovascular risks&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chemotherapy induced cardiomyopathy is a serious adverse effect of anticancer treatments with&#xD;
      poor long-term prognosis. In addition to the cumulative dose of anthracycline and&#xD;
      trastuzumab, cardiovascular risks have been proven to be the &quot;second hit&quot; when dealing with&#xD;
      chemotherapy related cardiomyopathy in breast cancer patients. Speckle-tracking&#xD;
      echocardiography have had robust evidence in diagnosis the early stage of left ventricular&#xD;
      dysfunction in various types of cancer treated by cardiotoxicity drugs. However, data is&#xD;
      still lacking regarding the role of speckle-tracking echocardiography in breast cancer&#xD;
      patients with cardiovascular risk&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of chemotherapy induced cardiomyopathy in breast cancer patients with cardiovascular risk</measure>
    <time_frame>two year follow-up</time_frame>
    <description>the incidence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The kinetics of global longitudinal strain (GLS) in breast cancer patients treated by anthracycline and/or trastuzumab</measure>
    <time_frame>two year follow-up</time_frame>
    <description>global longitudinal strain (percentage)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The cut-off value of global longitudinal strain (GLS) to predict chemotherapy induced cardiomyopathy in breast cancer patients treated by anthracycline and/or trastuzumab</measure>
    <time_frame>two year follow-up</time_frame>
    <description>global longitudinal strain (percentage)</description>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cardiomyopathy Due to Drug</condition>
  <condition>Breast Cancer</condition>
  <condition>Cardiovascular Risk Factor</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <description>2D Speckle-tracking echocardiography</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Breast cancer patients treated by anthracycline and/or trastuzumab with at least one of the&#xD;
        cardiovascular risk factors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Breast cancer patients treated by anthracycline and/or trastuzumab&#xD;
&#xD;
          -  Have at least one of these cardiovascular risks: age &gt; 60, hypertension, atrial&#xD;
             fibrillation, diabetes mellitus, dyslipidemia, chronic kidney disease, obesity, family&#xD;
             history of cardiovascular diseases.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 50% before chemotherapy&#xD;
&#xD;
          -  Chronic heart failure with NYHA functional class &gt;= II&#xD;
&#xD;
          -  Significant valvular stenosis/regurgitation&#xD;
&#xD;
          -  Acute heart failure due to acute coronary syndrome during follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hai H. Nguyen, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nhat M. Giang, M.D</last_name>
    <phone>+84919963999</phone>
    <email>minhnhat210189@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nguyen Hoang Hai</name>
      <address>
        <city>Ho Chi Minh</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nguyen H. Hai, Ph.D</last_name>
      <phone>+84-908247359</phone>
    </contact>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 6, 2020</study_first_submitted>
  <study_first_submitted_qc>September 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

